BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21536859)

  • 21. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes.
    Tremblay M; Tremblay CS; Herblot S; Aplan PD; Hébert J; Perreault C; Hoang T
    Genes Dev; 2010 Jun; 24(11):1093-105. PubMed ID: 20516195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer.
    Nottingham WT; Jarratt A; Burgess M; Speck CL; Cheng JF; Prabhakar S; Rubin EM; Li PS; Sloane-Stanley J; Kong-A-San J; de Bruijn MF
    Blood; 2007 Dec; 110(13):4188-97. PubMed ID: 17823307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1.
    Lécuyer E; Herblot S; Saint-Denis M; Martin R; Begley CG; Porcher C; Orkin SH; Hoang T
    Blood; 2002 Oct; 100(7):2430-40. PubMed ID: 12239153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Runx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver.
    Landry JR; Kinston S; Knezevic K; de Bruijn MF; Wilson N; Nottingham WT; Peitz M; Edenhofer F; Pimanda JE; Ottersbach K; Göttgens B
    Blood; 2008 Mar; 111(6):3005-14. PubMed ID: 18184866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
    Ferrando AA; Herblot S; Palomero T; Hansen M; Hoang T; Fox EA; Look AT
    Blood; 2004 Mar; 103(5):1909-11. PubMed ID: 14604958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
    Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
    Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
    Ferrando AA; Neuberg DS; Staunton J; Loh ML; Huard C; Raimondi SC; Behm FG; Pui CH; Downing JR; Gilliland DG; Lander ES; Golub TR; Look AT
    Cancer Cell; 2002 Feb; 1(1):75-87. PubMed ID: 12086890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset.
    Nagel S; Ehrentraut S; Meyer C; Kaufmann M; Drexler HG; MacLeod RA
    Leuk Lymphoma; 2015 Feb; 56(2):480-91. PubMed ID: 24844359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study.
    Bash RO; Hall S; Timmons CF; Crist WM; Amylon M; Smith RG; Baer R
    Blood; 1995 Jul; 86(2):666-76. PubMed ID: 7605997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
    Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
    Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis.
    Ballerini P; Blaise A; Busson-Le Coniat M; Su XY; Zucman-Rossi J; Adam M; van den Akker J; Perot C; Pellegrino B; Landman-Parker J; Douay L; Berger R; Bernard OA
    Blood; 2002 Aug; 100(3):991-7. PubMed ID: 12130513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1.
    Göttgens B; Broccardo C; Sanchez MJ; Deveaux S; Murphy G; Göthert JR; Kotsopoulou E; Kinston S; Delaney L; Piltz S; Barton LM; Knezevic K; Erber WN; Begley CG; Frampton J; Green AR
    Mol Cell Biol; 2004 Mar; 24(5):1870-83. PubMed ID: 14966269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
    Goldberg L; Tijssen MR; Birger Y; Hannah RL; Kinston SJ; Schütte J; Beck D; Knezevic K; Schiby G; Jacob-Hirsch J; Biran A; Kloog Y; Marcucci G; Bloomfield CD; Aplan PD; Pimanda JE; Göttgens B; Izraeli S
    Blood; 2013 Oct; 122(15):2694-703. PubMed ID: 23974202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice.
    Chervinsky DS; Zhao XF; Lam DH; Ellsworth M; Gross KW; Aplan PD
    Mol Cell Biol; 1999 Jul; 19(7):5025-35. PubMed ID: 10373552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice.
    O'Neil J; Billa M; Oikemus S; Kelliher M
    Oncogene; 2001 Jun; 20(29):3897-905. PubMed ID: 11439353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
    Hirose K; Inukai T; Kikuchi J; Furukawa Y; Ikawa T; Kawamoto H; Oram SH; Göttgens B; Kiyokawa N; Miyagawa Y; Okita H; Akahane K; Zhang X; Kuroda I; Honna H; Kagami K; Goi K; Kurosawa H; Look AT; Matsui H; Inaba T; Sugita K
    Blood; 2010 Aug; 116(6):962-70. PubMed ID: 20519628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish.
    Patterson LJ; Gering M; Eckfeldt CE; Green AR; Verfaillie CM; Ekker SC; Patient R
    Blood; 2007 Mar; 109(6):2389-98. PubMed ID: 17090656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
    Astolfi A; Vendemini F; Urbini M; Melchionda F; Masetti R; Franzoni M; Libri V; Serravalle S; Togni M; Paone G; Montemurro L; Bressanin D; Chiarini F; Martelli AM; Tonelli R; Pession A
    Oncotarget; 2014 Jan; 5(1):120-30. PubMed ID: 24334727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction.
    Lécuyer E; Larivière S; Sincennes MC; Haman A; Lahlil R; Todorova M; Tremblay M; Wilkes BC; Hoang T
    J Biol Chem; 2007 Nov; 282(46):33649-33658. PubMed ID: 17878155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.